On the other hand, aberrant activations of TLR7 and TLR9 have been implicated in type I IFN-related autoimmune diseases, such as systemic lupus erythematosus (SLE), which is characterized by the presence of autoantibodies against nucleic acids. This evidence concerns the gene TLR7 and systemic lupus erythematosus.